MarketCap
Facebook
X
Telegram
bluebird bio Operating Cycle | BLUE
Annual Operating Cycle bluebird bio
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 180 | 127 | 20.3 | 169 | 2.26 | 105 | 93.2 | 32.1 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 180 | 2.26 | 91.2 |
Quarterly Operating Cycle bluebird bio
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 553 | - | 338 | 102 | 95.4 | - | 260 | 126 | 44.9 | - | 64.3 | 9.01 | 14.1 | 42.6 | 172 | 1.4 K | 2.47 K | - | 741 | 628 | 476 | 32.9 | 36.9 | 24.7 | 13.2 | - | - | 36.5 | 31.2 | 50.7 | - | 12.7 | 30.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.47 K | 9.01 | 300 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Halozyme Therapeutics
HALO
|
347 | $ 101.68 | -1.26 % | $ 12.2 B |  USA |
 |
Hutchison China MediTech Limited
HCM
|
144 | $ 15.09 | -1.92 % | $ 13 B |  China |
 |
Aptorum Group Limited
APM
|
106 | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
3.46 K | $ 0.82 | 5.55 % | $ 85.3 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
71.2 | $ 0.02 | -56.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
178 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
465 | $ 26.14 | 3.24 % | $ 1.26 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
293 | $ 14.79 | 6.25 % | $ 1.32 B | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
8.01 K | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
115 | - | - | $ 5.18 B | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B |  Britain |
 |
BeiGene, Ltd.
BGNE
|
419 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
7.32 | $ 0.36 | -10.07 % | $ 26.4 K | USA |
 |
Cara Therapeutics
CARA
|
81.1 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
142 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
966 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
185 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
185 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
69.1 | - | 11.68 % | $ 8.97 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
309 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
5.1 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
2.28 K | - | - | $ 889 M | USA |
 |
Amicus Therapeutics
FOLD
|
932 | - | - | $ 4.47 B | USA |
 |
GlycoMimetics
GLYC
|
303 | - | 9357.83 % | $ 1.01 B | USA |
 |
Happiness Biotech Group Limited
HAPP
|
17 | - | 1.35 % | $ 17.8 M | China |
 |
Novavax
NVAX
|
85.6 | $ 9.97 | -2.25 % | $ 1.62 B | USA |